$OMI (Owens & Minor Inc.)

$OMI {{ '2016-04-20T15:12:40+0000' | timeago}} • Announcement

$OMI said it has been notified by a national healthcare-provider customer that the customer does not intend to renew its distribution agreement. The transition of this customer, which generated about $525MM in revenues to $OMI in 2015, is expected to begin in late 2016.

$VRTX {{ '2017-07-26T20:38:11+0000' | timeago}} • Announcement

$VRTX also reviewed its recent progress toward treating all people with cystic fibrosis, including the completion of an asset purchase agreement with Concert Pharmaceuticals for worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis.

$VRTX {{ '2017-07-26T20:36:21+0000' | timeago}} • Announcement

$VRTX lifted 2017 non-GAAP combined research & development and selling, general & administrative expenses outlook to $1.33-1.36Bil from $1.25-1.30Bil, and GAAP combined R&D and SG&A expenses estimate to $1.79-1.92 from $1.55-1.70. The updated forecast reflects the progression of the company's cystic fibrosis portfolio.

$VRTX {{ '2017-07-26T20:33:48+0000' | timeago}} • Announcement

$VRTX expects 2017 total cystic fibrosis product revenue of $1.84-2.07Bil, comprised of Orkambi and Kalydeco product revenues. $VRTX still expects 2017 product revenue for Orkambi of $1.1-1.3Bil and for Kalydeco of $740-770MM.

$VRTX {{ '2017-07-26T20:30:18+0000' | timeago}} • Announcement

$VRTX's net product revenues from cystic fibrosis therapy Orkambi for 2Q17 increased to $324.4MM from $245.5MM last year. This was primarily driven by the continued uptake in the medicine globally and additional uptake in people with cystic fibrosis ages 6 to 11 in the U.S., where approval was received in September 2016.

$VRTX {{ '2017-07-26T20:26:38+0000' | timeago}} • Announcement

$VRTX reported net income for 2Q17 of $31.17MM or $0.07 per share compared to a loss of $64.53MM or $0.26 per share last year. This swing in results was driven by higher revenue as well as a decline in interest expenses. Revenue grew to $544.14MM from $431.61MM. Non-GAAP EPS increased to $0.39 from $0.24.

$TMO {{ '2017-07-26T14:06:23+0000' | timeago}} • Webcast

$TMO said the upward revision of 2017 financial outlook mainly reflected the less adverse foreign exchange environment. The company continues to expect 4% organic revenue growth for the year. Excluding the effect of foreign exchange headwinds, adjusted EPS is seen growing 12-14%. Adjusted operating margin is forecast to grow 50-60 basis points YoY.

$TMO {{ '2017-07-26T13:46:17+0000' | timeago}} • Webcast

Scientific equipment maker $TMO said pharma and biotec continued to be its strongest end markets in 2Q17, with mid-single digits growth. The company's growth strategy remains centered on launching innovative products and leveraging the scale in Asia Pacific and emerging markets. In 2Q17, Thermo Fisher completed $250MM of share buybacks.

$BAX {{ '2017-07-26T12:58:04+0000' | timeago}} • Announcement

$BAX anticipates 2020 adjusted EPS of $3.25-3.40. $BAX also lifted its cash flow expectations for 2020 and now sees operating cash flow of about $2.65Bil. Capital expenditures are expected to total $650MM in 2020, resulting in free cash flow generation of about $2Bil, an increase of $250MM versus prior guidance.

$BAX {{ '2017-07-26T12:56:58+0000' | timeago}} • Announcement

As a result of ongoing business transformation efforts designed to accelerate performance, $BAX lifted its 2020 financial outlook. $BAX expects sales growth of 4% on a compounded annual basis from 2016 to 20202 and now sees adjusted operating margin in 2020 of about 20% as compared to previous guidance of 17-18%.

$BAX {{ '2017-07-26T12:55:25+0000' | timeago}} • Announcement

$BAX expects 3Q17 sales growth of about 4% on a reported basis, about 5% on a constant currency basis and about 6% operationally. The company expects earnings from continuing operations, before special items, of $0.58-0.60 per diluted share.

$BAX {{ '2017-07-26T12:54:23+0000' | timeago}} • Announcement

$BAX lifted 2017 EPS from continuing operations, before special items, guidance to $2.34-2.40 from $2.20-2.28. This guidance assumes the closure of the company's proposed acquisition of Claris Injectables, to be complete by the end of July 2017.

$BAX {{ '2017-07-26T12:52:56+0000' | timeago}} • Announcement

$BAX now expects 2017 sales growth of about 3% on a reported basis, about 4% on constant currency basis and about 5% operationally. Previously, the company had predicted sales growth of about 1-2% on a reported basis or 2-3% on a constant currency basis.

$TMO {{ '2017-07-26T12:48:19+0000' | timeago}} • Infographic

$TMO Thermo Fisher Scientific, Inc. Earnings AlphaGraphic: Q2 2017 highlights

$BAX {{ '2017-07-26T12:46:39+0000' | timeago}} • Announcement

$BAX's renal sales totaled $968MM, comparable to the prior year on reported basis and up 3% on both a constant currency basis and operational basis. Growth was driven by increased sales for in-center hemodialysis (HD) products in the US, international acute renal care sales and global sales of peritoneal dialysis (PD) therapies.

$BAX {{ '2017-07-26T12:45:36+0000' | timeago}} • Announcement

$BAX's global sales for Hospital Products totaled $1.6Bil in 2Q17, rising 1% on reported, 2% on constant currency and 4% operationally. This was driven by continued strength in US fluid systems business, favorable demand for parenteral nutrition therapies and pre-mixed injectable, as well as for select anesthesia and critical care products.

$BAX {{ '2017-07-26T12:42:25+0000' | timeago}} • Announcement

$BAX reported a 78% dip in 2Q17 earnings due to last year's net realized gains from exchange of its retained shares of Baxalta and contribution to its U.S. pension fund. Net income dropped to $265MM or $0.48 per share from $1.21Bil or $2.19 per share last year. Net sales rose 1% to $2.61Bil. Adjusted EPS grew 37% to $0.63.

$TMO {{ '2017-07-26T10:56:26+0000' | timeago}} • Announcement

Among $TMO’s business segments, Life Sciences Solutions posted a 3% YoY growth in 2Q17 revenues. Analytical Instruments segment revenues surged 47%, reflecting the acquisition of FEI Company last year. Revenues of the Specialty Diagnostics segment and Laboratory Products & Services segment advanced 1% and 4%, respectively, compared to 2Q16.

$TMO {{ '2017-07-26T10:42:34+0000' | timeago}} • Announcement

$TMO revised up its fiscal 2017 revenue guidance to the range of $19.71-$19.89Bil from the previous outlook of $19.51-$19.71Bil, indicating an 8-9% annual growth. The guidance of adjusted EPS has been raised to $9.15-$9.28 per share from the earlier forecast of $9.12-$9.28 per share, which will result in an 11-12% YoY increase.

$TMO {{ '2017-07-26T10:33:50+0000' | timeago}} • Announcement

Medical instruments maker $TMO reported strong results for 2Q17, continuing the recent trend. Earnings of the company, which is currently on an acquisition spree, jumped 20% YoY to $1.56 per share. Adjusted earnings, excluding special items, grew 13% to $2.3 per share. The bottom line growth was driven by a 10% increase in revenues to $4.99Bil.

$VRTX {{ '2017-07-25T21:51:58+0000' | timeago}} • Announcement

$VRTX and $CNCE completed an asset purchase agreement, under which $VRTX gained worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis. $CNCE received $160MM in cash upon closing and is eligible to receive up to $90MM in additional milestones.

Recent Transcripts

DGX (Quest Diagnostics Inc.)
Tuesday, July 25 2017 - 12:30pm
CNC (Centene Corp.)
Tuesday, July 25 2017 - 12:30pm
UNH (UnitedHealth Group Incorporated)
Tuesday, July 18 2017 - 12:45pm
FDX (FedEx Corporation)
Tuesday, June 20 2017 - 9:00pm
ENZ (Enzo Biochem Inc.)
Friday, June 9 2017 - 12:30pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
ARRY (Array BioPharma Inc.)
Wednesday, May 10 2017 - 1:00pm
STE (Steris Plc)
Tuesday, May 9 2017 - 2:00pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
CI (Cigna Corp.)
Friday, May 5 2017 - 12:30pm
MOH (Molina Healthcare, Inc.)
Thursday, May 4 2017 - 9:00pm
KERX (Keryx Biopharmaceuticals Inc.)
Thursday, May 4 2017 - 12:00pm
HUM (Humana Inc.)
Wednesday, May 3 2017 - 1:00pm
OMI (Owens & Minor Inc.)
Wednesday, May 3 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
WCG (WellCare Health Plans, Inc.)
Wednesday, May 3 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
HSKA (Heska Corporation)
Tuesday, May 2 2017 - 3:00pm
CAH (Cardinal Health, Inc.)
Monday, May 1 2017 - 12:30pm
IDXX (IDEXX Laboratories, Inc.)
Friday, April 28 2017 - 12:30pm

AlphaGraphics you may like